BRIEF published on 10/24/2026 at 13:05, 7 days 18 hours ago Nanobiotix Reports Final Phase 1 Results for NBTXR3 in Melanoma Clinical Trials Immunotherapy Melanoma NANOBIOTIX NBTXR3
PRESS RELEASE published on 10/24/2026 at 13:00, 7 days 19 hours ago NANOBIOTIX Announces Final Data from Phase 1 Study Evaluating JNJ-1900 (NBTXR3) With Immune Checkpoint Inhibitors as a 2L+ Therapy in Anti-PD-1-Resistant Primary Cutaneous Melanoma
BRIEF published on 10/20/2026 at 22:20, 11 days 9 hours ago Information on Nanobiotix Capital Voting Rights Euronext Actions Nasdaq NANOBIOTIX
BRIEF published on 10/20/2026 at 22:20, 11 days 9 hours ago Voting Rights and Shares Capital of NANOBIOTIX Voting Rights Euronext Nasdaq Shares Capital NANOBIOTIX
PRESS RELEASE published on 10/20/2026 at 22:15, 11 days 9 hours ago Voting Rights and Shares Capital of the Company Nanobiotix reports voting rights and shares capital. Company listed on Euronext Paris and Nasdaq. Focus on disruptive therapeutic approaches. Headquarters in Paris, France Euronext Paris Voting Rights Nasdaq Shares Capital NANOBIOTIX
BRIEF published on 10/01/2026 at 22:20, 30 days 9 hours ago NANOBIOTIX Appoints Arnd Christ as CFO Biotechnology CFO Appointment Financial Leadership NANOBIOTIX Arnd Christ
BRIEF published on 10/01/2026 at 22:20, 30 days 9 hours ago NANOBIOTIX appoints Arnd Christ as Chief Financial Officer Chief Financial Officer Biotechnology Appointment NANOBIOTIX Arnd Christ
PRESS RELEASE published on 10/01/2026 at 22:15, 30 days 9 hours ago NANOBIOTIX Announces the Appointment of Arnd Christ as Chief Financial Officer Nanobiotix appoints Arnd Christ as CFO, bringing extensive financial leadership experience to advance treatment platforms for patients with cancer and major diseases CFO Cancer Treatment Financial Leadership NANOBIOTIX Arnd Christ
BRIEF published on 09/24/2026 at 22:20, 1 month 6 days ago NANOBIOTIX Reports First Half 2026 Operational and Financial Progress Cancer Treatment Financial Update NANOBIOTIX Phase 1 Study JNJ-1900 (NBTXR3)
PRESS RELEASE published on 09/24/2026 at 22:15, 1 month 6 days ago NANOBIOTIX Provides First Half 2026 Operational and Financial Update Nanobiotix provides operational and financial update for first half of 2026, showcasing progress in clinical development and successful global offering, reinforcing position in cancer treatment innovation Cancer Treatment Clinical Development Operational Update Financial Update NANOBIOTIX
Published on 10/30/2026 at 23:35, 1 day 8 hours ago Prospect Ridge Announces Closing of Critical Metals Flow-through Unit Private Placement
Published on 10/30/2026 at 23:30, 1 day 8 hours ago Revolve Enters into Definitive Agreement to Acquire Three Project, 6 MW Battery Storage Portfolio in Ontario
Published on 10/30/2026 at 19:00, 1 day 13 hours ago Electric Royalties Ltd. Announces Application for Warrant Extension
Published on 10/30/2026 at 15:30, 1 day 16 hours ago Bluejay Diagnostics Announces 1-for-4 Reverse Stock Split
Published on 11/01/2026 at 05:00, 3 hours 2 minutes ago 2026 Yangtze River Culture Festival Opens in Yonglian Village, Zhangjiagang, Jiangsu
Published on 10/31/2026 at 16:35, 15 hours 27 minutes ago SKYWORTH Solar Announces Global Launch of Solavita as a Smart Microgrid Brand
Published on 10/30/2026 at 22:49, 1 day 9 hours ago EQS-Adhoc: STRATEC SELLS LOSS-MAKING BUSINESS, RECOGNIZES IMPAIRMENTS, AND AMENDS GUIDANCE
Published on 10/30/2026 at 23:00, 1 day 9 hours ago BIOPHYTIS REPORTS FIRST- HALF 2026 RESULTS AND PROVIDES AN UPDATE ON ITS STRATEGY
Published on 10/30/2026 at 12:00, 1 day 20 hours ago Capital increase through exercise of subscription rights
